EUVIMEDOpdag EUVIMED
Open access · CC BY-NC 4.0

The Molecular and Clinical Impact of Atorvastatin Exposure on Paclitaxel Neurotoxicity in Sensory Neurons and Cancer Patients

Emma Simonsen iD, Christina Mortensen iD, Cathrine Lundgaard Riis, Karina Dahl Steffensen iD, Morten Olesen iD, Martin Thomsen Ernst iD, Tore Bjerregaard Stage iD, Anton Pottegård iD

Basic & Clinical Pharmacology & Toxicology · 2025

DOI: 10.1111/bcpt.70022 ↗

At a glance

Journal article in Basic & Clinical Pharmacology & Toxicology, 2025. Written by Emma Simonsen and 7 co-authors. Institution: Department of Public Health, Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, Odense, Denmark. Major MEDLINE topics: Atorvastatin, Paclitaxel, Sensory Receptor Cells, Neurotoxicity Syndromes. 28 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Danish Cancer Society, Odense University Hospital Fund for Pre-graduate Stipends, Kræftens Bekæmpelse.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Recent evidence suggests that atorvastatin exacerbates paclitaxel neurotoxicity via P‐glycoprotein inhibition. We used a translational approach to investigate if atorvastatin or simvastatin exacerbates (i) paclitaxel neurotoxicity in human sensory neurons and (ii) paclitaxel‐induced peripheral neuropathy (PIPN) in cancer patients. Paclitaxel neurotoxicity was assessed by quantifying neuronal networks of human induced pluripotent stem cell‐derived sensory neurons (iPSC‐SNs) with and without atorvastatin or simvastatin exposure. We estimated the odds ratio (OR) of early paclitaxel discontinuation due to PIPN in a nationwide cohort of paclitaxel‐treated women (2014–2018), comparing atorvastatin users to simvastatin users and nonusers of statins. Only the highest concentration of atorvastatin (100 nM) significantly exacerbated paclitaxel neurotoxicity in iPSC‐SNs ( p < 0.05). Among 576 paclitaxel‐treated women, atorvastatin use was not significantly associated with early paclitaxel discontinuation due to PIPN, with adjusted ORs of 0.80 [95% confidence interval (CI) 0.34–1.88] compared with simvastatin, and 1.24 [95% CI 0.44–3.53] compared with nonuse. Supplementary analyses showed varying but statistically nonsignificant results. Our in vitro findings suggest that atorvastatin, not simvastatin, significantly worsens paclitaxel neurotoxicity. However, no link was found between atorvastatin use and early paclitaxel discontinuation due to PIPN. Larger, well‐designed studies are required to clarify the discrepancy between in vitro and clinical data and the inconsistencies with previous clinical evidence.

Subjects

MeSH terms (MEDLINE)

AtorvastatinPaclitaxelSensory Receptor CellsNeurotoxicity SyndromesPeripheral Nervous System DiseasesAntineoplastic Agents, PhytogenicHydroxymethylglutaryl-CoA Reductase InhibitorsNeoplasmsHumansFemaleMiddle AgedSimvastatinAgedInduced Pluripotent Stem CellsAdultCohort Studies

Author keywords

chemotherapyneurotoxicitypaclitaxelperipheral neuropathysensory neuronsstatinstranslational research

Substances

AtorvastatinPaclitaxelSimvastatinAntineoplastic Agents, PhytogenicHydroxymethylglutaryl-CoA Reductase Inhibitors

Authors and institutions

  • Department of Public Health, Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, Odense, Denmark.
  • Department of Oncology, Lillebaelt University Hospital of Southern Denmark, Vejle, Denmark.
  • Department of Regional Health Research, University of Southern Denmark, Odense, Denmark.
  • Department of Clinical Pharmacology, Odense University Hospital, Odense, Denmark.

ORCID profiles: Emma Simonsen, Christina Mortensen, Karina Dahl Steffensen, Morten Olesen, Martin Thomsen Ernst, Tore Bjerregaard Stage, Anton Pottegård

Funding

  • Danish Cancer Society
  • Odense University Hospital Fund for Pre-graduate Stipends
  • Kræftens Bekæmpelse

Cite

APA

Simonsen, E., Mortensen, C., Riis, C. L., Steffensen, K. D., Olesen, M., Ernst, M. T., Stage, T. B., & Pottegård, A. (2025). The Molecular and Clinical Impact of Atorvastatin Exposure on Paclitaxel Neurotoxicity in Sensory Neurons and Cancer Patients. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.70022

Vancouver

Simonsen E, Mortensen C, Riis CL, Steffensen KD, Olesen M, Ernst MT, et al. The Molecular and Clinical Impact of Atorvastatin Exposure on Paclitaxel Neurotoxicity in Sensory Neurons and Cancer Patients. Basic & Clinical Pharmacology & Toxicology. 2025. doi:10.1111/bcpt.70022

BibTeX
@article{Simonsen2025,
  author = {Simonsen, Emma and Mortensen, Christina and Riis, Cathrine Lundgaard and Steffensen, Karina Dahl and Olesen, Morten and Ernst, Martin Thomsen and Stage, Tore Bjerregaard and Pottegård, Anton},
  title = {The Molecular and Clinical Impact of Atorvastatin Exposure on Paclitaxel Neurotoxicity in Sensory Neurons and Cancer Patients},
  journal = {Basic & Clinical Pharmacology & Toxicology},
  year = {2025},
  doi = {10.1111/bcpt.70022}
}
Start for free →